RVV — Revive Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$8.71m
- CA$8.71m
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure
Brief: Revive Therapeutics To Investigate Bucillamine’S Potential In Cancer Treatment
Brief: Revive Therapeutics Announces LOI To Acquire Diagnamed’S Molecular Hydrogen Program
Brief: Revive Therapeutics Announces Update On Research And Development Focus On Bucillamine
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure
Brief: Revive Therapeutics Provides Update On FDA Type C Meeting For Clinical Study Of Bucillamine To Treat Long Covid
Brief: Revive Therapeutics Provides Update From FDA Meeting For Long Covid Diagnostic Product
Brief: Revive Therapeutics Submits Type C Meeting Request Package To US FDA For Clinical Study Of Bucillamine To Treat Long COVID
Brief: Revive Therapeutics Provides Corporate Update
Brief: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
Brief: Revive Therapeutics Enters into Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize Novel Long COVID Rapid Test
Brief: Revive Therapeutics Provides Update Of Novel Bucillamine Formulation Development
Revive Therapeutics' experimental COVID treatment fails in late-stage study (updated)
Brief: Revive Therapeutics Announces Results Of Phase 3 Clinical Study For Bucillamine In The Treatment Of COVID-19
Revive Therapeutics' experimental COVID treatment fails in late-stage study